Acura Stock Story

All Stories . Risk . 
Vlad Skutelnik .  Story
ACUR
 Stock
  

USD 0.10  0.05  100.00%   

By Vlad Skutelnik
Macroaxis Story
It seems Acura Pharma will continue to recover much faster as its share price surged up 4.17% today. Acura Pharma Cmn current daily volatility is 12.03 percent, with a beta of -1.1 and an alpha of 0.73 over DOW. As many investors are getting excited about pharmaceutical products, it is fair to sum up Acura Pharma Cmn. We will evaluate why recent Acura Pharma price moves suggest a bounce in August.
Published over a month ago
View all stories for Acura Pharma | View All Stories

Is Acura Pharma (OTC:ACUR) a new disruptor?

Acura Pharma Cmn currently holds roughly 89 K in cash with (396 K) of positive cash flow from operations.
Acura Pharma holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.1039, which signifies a somewhat significant risk relative to the market. Let's try to break down what Acura's beta means in this case. As the market becomes more bullish, returns on owning Acura Pharma are expected to decrease slowly. On the other hand, during market turmoil, Acura Pharma is expected to outperform it slightly. Although it is vital to follow Acura Pharma Cmn historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Acura Pharma Cmn expected return of 1.17 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Acura Pharma value at risk, as well as the relationship between the skewness and day median price to analyze future returns on Acura Pharma.
Investing in Acura Pharma, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Acura Pharma along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Acura Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Acura Pharma in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
Naive
Forecast
Details
1 Analysts
Consensus
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acura Pharma. Your research has to be compared to or analyzed against Acura Pharma's peers to derive any actionable benefits. When done correctly, Acura Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Acura Pharma Cmn.

Watch out for price decline

Please consider monitoring Acura Pharma on a daily basis if you are holding a position in it. Acura Pharma is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Acura Pharma stock to be traded above the $1 level to remain listed. If Acura Pharma stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Acura Pharma's Liquidity

Acura Pharma financial leverage refers to using borrowed capital as a funding source to finance Acura Pharma Cmn ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acura Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Acura Pharma's total debt and its cash.

How does Acura utilize its cash?

To perform a cash flow analysis of Acura Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Acura Pharma is receiving and how much cash it distributes out in a given period. The Acura Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Acura Pharma Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Acura Pharma reported last year Net Cash Flow from Operations of (647,100)

Acura Pharma Correlation with Peers

Investors in Acura can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Acura Pharma Cmn. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Acura Pharma and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Acura is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Acura for more details

Detailed Outlook On Acura Pharma

Acura Pharma is abnormally volatile given 3 months investment horizon. Acura Pharma Cmn secures Sharpe Ratio (or Efficiency) of 0.097, which signifies that the company had 0.097% of return per unit of risk over the last 3 months. Our standpoint towards foreseeing the risk of a stock is to use both market data as well as company specific technical data. We are able to break down and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.17% are justified by taking the suggested risk. Use Acura Pharma Risk Adjusted Performance of 0.1227, mean deviation of 7.04, and Downside Deviation of 14.55 to evaluate company specific risk that cannot be diversified away.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Another 3 percent spike for Acura Pharma

Acura Pharma latest semi variance advances over 71.08.
As of the 3rd of July, Acura Pharma shows the Downside Deviation of 14.55, risk adjusted performance of 0.1227, and Mean Deviation of 7.04. Acura Pharma Cmn technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Acura Pharma Cmn, which can be compared to its rivals. Please confirm Acura Pharma Cmn variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Acura Pharma Cmn is priced correctly, providing market reflects its regular price of 0.5 per share. As Acura Pharma Cmn is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Our Bottom Line On Acura Pharma Cmn

While some other firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Acura Pharma may offer a potential longer-term growth to retail investors. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Acura nor short your existing holdings in the OTC Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Acura Pharma.

Editorial Staff

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Acura Pharma Cmn. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2022 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY